As the year progressed, the overall robust capabilities of the pharmacy industry and FDA regulators allowed drug development to remain at near-normal levels. (Image: Shutterstock)
Despite concerns about the effect of COVID-19 on the FDA's work in approving new pharmaceutical treatments, 2020 did not see a major drop-off in approvals, according to a new report from OptumRx.
OptumRx, a pharmacy benefits manager owned by UnitedHealth Group, recently released its OptumRx Drug Pipeline Insights Report. In addition to reporting on the general pace of approval of new drugs, it highlighted five notable drugs being reviewed by the FDA and their possible impact on the market in 2021.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
